BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

611 related articles for article (PubMed ID: 26695153)

  • 21. Decreased circadian component Bmal1 predicts tumor progression and poor prognosis in human pancreatic ductal adenocarcinoma.
    Li W; Liu L; Liu D; Jin S; Yang Y; Tang W; Gong L
    Biochem Biophys Res Commun; 2016 Mar; 472(1):156-62. PubMed ID: 26915801
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Clinicopathological significance of ISYNA1 expression in pancreatic ductal adenocarcinoma].
    Zhou L; Sheng WW; Shi XY; Zhou JP; Dong M
    Zhonghua Wai Ke Za Zhi; 2019 Mar; 57(3):206-211. PubMed ID: 30861650
    [No Abstract]   [Full Text] [Related]  

  • 23. Low expression of IGFBP7 is associated with poor outcome of pancreatic ductal adenocarcinoma.
    An W; Ben QW; Chen HT; Zheng JM; Huang L; Li GX; Li ZS
    Ann Surg Oncol; 2012 Nov; 19(12):3971-8. PubMed ID: 22622471
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High nuclear Survivin expression as a poor prognostic marker in pancreatic ductal adenocarcinoma.
    Zhou L; Lu J; Liang ZY; Zhou WX; Yuan D; Li BQ; You L; Guo JC; Zhao YP
    J Surg Oncol; 2018 Dec; 118(7):1115-1121. PubMed ID: 30261114
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mortalin expression in pancreatic cancer and its clinical and prognostic significance.
    Cui X; Li Z; Piao J; Li J; Li L; Lin Z; Jin A
    Hum Pathol; 2017 Jun; 64():171-178. PubMed ID: 28412209
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Jagged1 and DLL4 expressions in benign and malignant pancreatic lesions and their clinicopathological significance.
    Huang SF; Yang ZL; Li DQ; Liu ZY; Wang CW; Miao XY; Zou Q; Yuan Y
    Hepatobiliary Pancreat Dis Int; 2016 Dec; 15(6):640-646. PubMed ID: 27919854
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stromal fibronectin expression in patients with resected pancreatic ductal adenocarcinoma.
    Hu D; Ansari D; Zhou Q; Sasor A; Said Hilmersson K; Andersson R
    World J Surg Oncol; 2019 Feb; 17(1):29. PubMed ID: 30736807
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NF45 overexpression is associated with poor prognosis and enhanced cell proliferation of pancreatic ductal adenocarcinoma.
    Wan C; Gong C; Ji L; Liu X; Wang Y; Wang L; Shao M; Yang L; Fan S; Xiao Y; Wang X; Li M; Zhou G; Zhang Y
    Mol Cell Biochem; 2015 Dec; 410(1-2):25-35. PubMed ID: 26276310
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overexpression of FOXM1 is associated with poor prognosis and clinicopathologic stage of pancreatic ductal adenocarcinoma.
    Xia JT; Wang H; Liang LJ; Peng BG; Wu ZF; Chen LZ; Xue L; Li Z; Li W
    Pancreas; 2012 May; 41(4):629-35. PubMed ID: 22249132
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Arpin downregulation is associated with poor prognosis in pancreatic ductal adenocarcinoma.
    Zhang SR; Li H; Wang WQ; Jin W; Xu JZ; Xu HX; Wu CT; Gao HL; Li S; Li TJ; Zhang WH; Xu SS; Ni QX; Yu XJ; Liu L
    Eur J Surg Oncol; 2019 May; 45(5):769-775. PubMed ID: 30416079
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overexpression of B2M and loss of ALK7 expression are associated with invasion, metastasis, and poor-prognosis of the pancreatic ductal adenocarcinoma.
    Liu C; Yang Z; Li D; Liu Z; Miao X; Yang L; Zou Q; Yuan Y
    Cancer Biomark; 2015; 15(6):735-43. PubMed ID: 26406402
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Toll-like receptor 2 and Toll-like receptor 4 predict favorable prognosis in local pancreatic cancer.
    Lanki MA; Seppänen HE; Mustonen HK; Böckelman C; Juuti AT; Hagström JK; Haglund CH
    Tumour Biol; 2018 Sep; 40(9):1010428318801188. PubMed ID: 30246618
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma.
    Zhang Y; Xu J; Hua J; Liu J; Liang C; Meng Q; Wei M; Zhang B; Yu X; Shi S
    J Immunother Cancer; 2019 Aug; 7(1):233. PubMed ID: 31464648
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HBXIP protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas.
    Zhou X; Wang X; Duan J; Sun W; Chen Z; Li Q; Ou Z; Jiang G; Ren X; Liu S
    Pathol Res Pract; 2019 Feb; 215(2):343-346. PubMed ID: 30583814
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of microRNA-218 in human pancreatic ductal adenocarcinoma and its correlation with tumor progression and patient survival.
    Zhu Z; Xu Y; Du J; Tan J; Jiao H
    J Surg Oncol; 2014 Feb; 109(2):89-94. PubMed ID: 24166773
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Decreased TIP30 expression predicts poor prognosis in pancreatic cancer patients.
    Guo S; Jing W; Hu X; Zhou X; Liu L; Zhu M; Yin F; Chen R; Zhao J; Guo Y
    Int J Cancer; 2014 Mar; 134(6):1369-78. PubMed ID: 24037692
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High expression of DDR1 is associated with the poor prognosis in Chinese patients with pancreatic ductal adenocarcinoma.
    Huo Y; Yang M; Liu W; Yang J; Fu X; Liu D; Li J; Zhang J; Hua R; Sun Y
    J Exp Clin Cancer Res; 2015 Aug; 34(1):88. PubMed ID: 26297342
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Clinical and Pathological Significance of Nectin-2 and DDX3 Expression in Pancreatic Ductal Adenocarcinomas.
    Liang S; Yang Z; Li D; Miao X; Yang L; Zou Q; Yuan Y
    Dis Markers; 2015; 2015():379568. PubMed ID: 26294807
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neutrophils infiltrating pancreatic ductal adenocarcinoma indicate higher malignancy and worse prognosis.
    Wang Y; Fang T; Huang L; Wang H; Zhang L; Wang Z; Cui Y
    Biochem Biophys Res Commun; 2018 Jun; 501(1):313-319. PubMed ID: 29738769
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CXCR4--A Prognostic and Clinicopathological Biomarker for Pancreatic Ductal Adenocarcinoma: A Meta-Analysis.
    Krieg A; Riemer JC; Telan LA; Gabbert HE; Knoefel WT
    PLoS One; 2015; 10(6):e0130192. PubMed ID: 26091099
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.